[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564959":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":85,"collaborators":87,"id":91,"slug":7,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":92,"sex":97,"minAge":98,"maxAge":7,"enrollmentInfo":99,"targetDuration":7,"studyType":102,"phases":7,"briefSummary":103,"conditions":104,"keywords":110,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"Oxford Biodynamics Inc.","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Ryan Mathis, MD","Oxford BioDynamics","STUDY_DIRECTOR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","888-200-3361","ryan.mathis@myobdx.com",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"Joseph DeSimone, BA","803-329-7772","joseph@ccorn.net",[23,49,68],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Eastern Connecticut Hematology and Oncology","RECRUITING","Norwich","Connecticut","06360","United States",{"type":31,"coordinates":32},"Point",[33,34],-72.07591,41.52426,{"lat":34,"lon":33},[37,41,46],{"name":38,"role":15,"phone":39,"phoneExt":7,"email":40},"Susan Johnson, MD","(860) 886-8362","sjohnson@echoct.com",{"name":42,"role":15,"phone":43,"phoneExt":44,"email":45},"Stephanie Pacheco","860-886-8362","253","SPacheco@echoct.com",{"name":47,"role":48,"phone":7,"phoneExt":7,"email":7},"Dennis Slater, MD","PRINCIPAL_INVESTIGATOR",{"facility":50,"status":25,"city":51,"state":52,"zip":53,"country":29,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Cancer Center of Middle Georgia","Dublin","Georgia","31021",{"type":31,"coordinates":55},[56,57],-82.90375,32.54044,{"lat":57,"lon":56},[60,64,67],{"name":61,"role":15,"phone":62,"phoneExt":7,"email":63},"Harsha Vyas, MD","(478) 272-8266","hvyas@ccmgeorgia.com",{"name":65,"role":15,"phone":62,"phoneExt":7,"email":66},"Audrey Bryan, BS","abryan@ccmgeorgia.com",{"name":61,"role":48,"phone":7,"phoneExt":7,"email":7},{"facility":69,"status":25,"city":70,"state":71,"zip":72,"country":29,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Carolina Blood and Cancer Care Associates","Rock Hill","South Carolina","29732",{"type":31,"coordinates":74},[75,76],-81.02508,34.92487,{"lat":76,"lon":75},[79,82,84],{"name":80,"role":15,"phone":20,"phoneExt":7,"email":81},"Sashi Naidu, MD","snaidu@cbcca.net",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":83},"jdesimone@cbcca.net",{"name":80,"role":48,"phone":7,"phoneExt":7,"email":7},{"type":86,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[88],{"name":89,"class":90},"Community Clinical Oncology Research Network, LLC","UNKNOWN","100564959",false,"NCT06635954","A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.","PROWES","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Stage III or IV cancer\n3. Selected by their healthcare provider to receive the Episwitch CiRT® test according to the current evidence-based schedule (per protocol) as part of their standard of practice.\n4. ECOG performance status ≤ 2\n5. Clinically eligible for ICI therapy\n6. Able to read, understand and provide written informed consent.\n7. Willing and able to comply with the study requirements\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding\n2. History of bone marrow or organ transplant\n3. Contra indication for receiving Immune Check Point inhibitor.","ALL","18 Years",{"count":100,"type":101},2000,"ESTIMATED","OBSERVATIONAL","The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.",[105,106,107,108,109],"Cancer","Immunotherapy","PD-1","PD-L1","Immune Checkpoint Therapy",[111,112,113,114,115,116,117,118,119,120,107,108],"immunotherapy","immune checkpoint inhibitor","ICI therapy","ICI","Immune Checkpoint Inhibitor therapy","Episwitch","Episwitch CiRT","Immune Related Adverse Event","IRAE","cancer","2025-03-12",{"date":123,"type":124},"2025-03-17","ACTUAL",{"date":126,"type":124},"2024-05-14",{"date":128,"type":101},"2027-05-14",{"name":5,"class":6},3]